Trial Group - Lymphoma

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.

Indolent (grow slowly) Non-Hodgkin’s Lymphoma that have returned after previous treatment.

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with standard immunochemotherapy.

Indolent B-cell non-Hodgkin’s lymphoma that has returned.

The purpose of this trial is to find out if the drug copanlisib in combination with rituximab is superior to placebo in combination with rituximab.